Interleukin-6 gene -174 C/G and apolipoprotein E gene polymorphisms and the risk of Alzheimer disease in a Polish population

Neurologia i Neurochirurgia Polska

Volumn 44, Issue 6, 2010, Pages 537-541

  Klimkowicz Mrowiec, Aleksandra ^a   Wołkow, Paweł ^b   Spisak, Karolina ^a   Maruszak, Aleksandra ^c   Styczyńska, Maria ^c   Barcikowska, Maria ^c   Szczudlik, Andrzej ^b   Słowik, Agnieszka ^b  

^a UNIVERSITY HOSPITAL IN KRAKOW   (Poland)

^b JAGIELLONIAN UNIVERSITY   (Poland)

^c MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Alzheimer disease; APOE; Interleukin 6; Polish population; Polymorphism; Risk factor

Indexed keywords

APOLIPOPROTEIN E; INTERLEUKIN 6;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; BACTERIAL GENE; COGNITIVE DEFECT; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 78651237486     PISSN: 00283843     EISSN: 18974260     Source Type: Journal    
DOI: 10.1016/S0028-3843(14)60149-3     Document Type: Article

References (33)

1. Sheng J.G., Griffin W.S., Royston M.C., et al. Distribution of interleukin-1-immunoreactive microglia in cerebral cortical layers: implications for neuritic plaque formation in Alzheimer's disease. Neuropathol Appl Neurobiol 1998; 24: 278-283.
2. Rogers J., Webster S., Lue L.F., et al. Inflammation and Alzheimer's disease pathogenesis. Neurobiol Aging 1996; 17: 681-686.
3. Hüll M., Berger M., Volk B., et al. Occurrence of interleukin-6 in cortical plaques of Alzheimer's disease patients may precede transformation of diffuse into neuritic plaques. Ann N Y Acad Sci 1996; 17: 205-212.
4. Bauer J., Strauss S., Schreiter-Gasser U., et al. Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett 1991; 8: 111-114.
5. Hampel H., Haslinger A., Scheloske M., et al. Pattern of interleukin-6 receptor complex immunoreactivity between cortical regions of rapid autopsy normal and Alzheimer's disease brain. Eur Arch Psychiatry Clin Neurosci 2005; 255: 269-278.
6. Luterman J.D., Haroutunian V., Yemul S., et al. Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. Arch Neurol 2000; 57: 1153-1160. (Pubitemid 30644662)
7. Weaver J.D., Huang M.H., Albert M., et al. Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. Neurology 2002; 13: 371-378. (Pubitemid 34857929)
8. Engelhart M.J., Geerlings M.I., Meijer J., et al. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study. Arch Neurol 2004; 61: 668-672.
9. Baranowska-Bik A., Bik W., Wolinska-Witort E., et al. Plasma beta amyloid and cytokine profile in women with Alzheimer's disease. Neuro Endocrinol Lett 2008; 29: 75-79.
10. Bermejo P., Martín-Aragón S., Benedí J., et al. Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease. Immunol Lett 2008; 15: 198-202.
11. Licastro F., Pedrini S., Caputo L., et al. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-anti chymo trypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? J Neuroimmunol 2000; 1: 97-102.
12. Blum-Degen D., Müller T., Kuhn W., et al. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 1995; 202: 17-20. (Pubitemid 26014811)
13. Fishman D., Faulds G., Jeffery R., et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemiconset juvenile chronic arthritis. J Clin Invest 1998; 102: 1369-1376.
14. Capurso C., Solfrizzi V., D'Introno A., et al. Interleukin 6-174 G/C promoter gene polymorphism and sporadic Alzheimer's disease: geographic allele and genotype variations in Europe. Exp Gerontol 2004; 39: 1567-1573.
15. Arosio B., Trabattoni D., Galimberti L., et al. Interleukin-10 and interleukin-6 gene polymorphisms as risk factors for Alzheimer's disease. Neurobiol Aging 2004; 25: 1009-1015. (Pubitemid 38798062)
16. Faltraco F., Bürger K., Zill P., et al. Interleukin-6-174 G/C promoter gene polymorphism C allele reduces Alzheimer's disease risk. J Am Geriatr Soc 2003; 51: 578-579.
17. Licastro F., Grimaldi L.M., Bonafè M., et al. Interleukin-6 gene alleles affect the risk of Alzheimer's disease and levels of the cytokine in blood and brain. Neurobiol Aging 2003; 24: 921-926. (Pubitemid 36962977)
18. Pola R., Flex A., Gaetani E., et al. The -174 G/C polymorphism of the interleukin-6 gene promoter is associated with Alzheimer's disease in an Italian population [corrected]. Neuroreport 2002; 16: 1645-1647.
19. Shibata N., Ohnuma T., Takahashi T., et al. Effect of IL-6 polymorphism on risk of Alzheimer disease: genotype-phenotype association study in Japanese cases. Am J Med Genet 2002; 8: 436-439.
20. Koivisto A.M., Helisalmi S., Pihlajamäki J., et al. Interleukin-6 promoter polymorphism and late-onset Alzheimer's disease in the Finnish population. J Neurogenet 2005; 19: 155-161.
21. Zhang Y., Hayes A., Pritchard A., et al. Interleukin-6 promoter polymorphism: risk and pathology of Alzheimer's disease. Neurosci Lett 2004; 20: 99-102.
22. Bhojak T.J., DeKosky S.T., Ganguli M., et al. Genetic polymorphisms in the cathespin D and interleukin-6 genes and the risk of Alzheimer's disease. Neurosci Lett 2000; 7: 21-24. (Pubitemid 30408429)
23. Depboylu C., Lohmüller F., Gocke P., et al. An interleukin-6 promoter variant is not associated with an increased risk for Alzheimer's disease. Dement Geriatr Cogn Disord 2004; 17: 170-173. (Pubitemid 38339743)
24. Paradowski B., Celczyñska D., Dobosz T., et al. Polymorphism 174 G/C of interleukin 6 gene in Alzheimer's disease - preliminary report. Neurol Neurochir Pol 2008; 42: 312-315.
25. Bagli M., Papassotiropoulos A., Knapp M., et al. Association between an interleukin-6 promoter and 3' flanking region haplotype and reduced Alzheimer's disease risk in a German population. Neurosci Lett 2000; 7: 109-112. (Pubitemid 30156745)
26. van Oijen M., Hofman A., Soares H.D., et al. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective casecohort study. Lancet Neurol 2006; 5: 655-660.
27. Ravaglia G., Paola F., Maioli F., et al. Interleukin-1beta and interleukin-6 gene polymorphisms as risk factors for AD: a prospective study. Exp Gerontol 2006; 41: 85-92.
28. Capurso C., Solfrizzi V., Colacicco A.M., et al. Interleukin 6-174 G/C promoter and variable number of tandem repeats (VNTR) gene polymorphisms in sporadic Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2010; 1: 177-182.
29. McKhann G., Drachman D., Folstein M., et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force of Alzheimer's disease. Neurology 1984; 34: 939-944.
30. Klimkowicz-Mrowiec A., Slowik A., Krzywoszañski L., et al. Severity of explicit memory impairment due to Alzheimer's disease improves effectiveness of implicit learning. J Neurol 2008; 20: 234-240.
31. Folstein M.F., Folstein S.E., McHugh P.R. 'Mini Mental State': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
32. Poirier J., Davignon J., Bouthillier D., et al. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993; 18: 697-699.
33. Brousseau T., Legrain S., Berr C., et al. Confirmation of the epsilon 4 allele of the apolipoprotein E gene as a risk factor for late-onset Alzheimer's disease. Neurology 1994; 44: 342-344.